HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained an $18 price target.
August 15, 2023 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The reiterated 'Buy' rating and maintained $18 price target by HC Wainwright & Co. could potentially boost investor confidence in Capricor Therapeutics.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiterated 'Buy' rating and maintained $18 price target by HC Wainwright & Co. indicates their continued confidence in Capricor Therapeutics, which could potentially boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100